CTOs on the Move

BioElectron Technology Corporation

www.bioelectron.com

 
BioElectron is a platform biotechnology company, with expertise in the electron transfer (redox) chemical reactions that underpin oxidative stress and inflammation in all biological systems.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BioElectron Technology Corporation raised $40M on 08/10/2018

Similar Companies

Phycotransgenics

Phycotransgenics, LLC is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Afrivax

Afrivax is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PSI CRO AG

PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSIs global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSIs reputation is that of a no-nonsense​ CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Empirico

Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development.